Holen Sie sich die Stockscreener-App
5.11
0.00%
0.00
Vorhandelsmarkt:
5.06
-0.05
-0.98%
Schlusskurs vom Vortag:
$5.11
Offen:
$5.1
24-Stunden-Volumen:
282.16K
Relative Volume:
0.63
Marktkapitalisierung:
$304.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.80M
KGV:
-6.8133
EPS:
-0.75
Netto-Cashflow:
$-30.67M
1W Leistung:
-2.11%
1M Leistung:
-2.29%
6M Leistung:
+50.29%
1J Leistung:
+51.63%
1-Tages-Spanne:
$4.95
$5.2184
1-Wochen-Bereich:
$4.95
$5.58
52-Wochen-Spanne:
$2.71
$6.5476
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Firmenname
Aldeyra Therapeutics Inc
Sektor
Branche
Telefon
781-761-4904
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Vergleichen Sie ALDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.11 | 304.30M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-04-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-30 | Eingeleitet | Jefferies | Buy |
| 2020-10-16 | Eingeleitet | BTIG Research | Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-04 | Eingeleitet | Citigroup | Buy |
| 2018-09-26 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Janney | Buy |
| 2018-01-26 | Eingeleitet | Seaport Global Securities | Buy |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-01 | Eingeleitet | Stifel | Buy |
| 2015-07-01 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-03-20 | Bestätigt | H.C. Wainwright | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-06-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $6.01 Million Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
3 US Penny Stocks With Market Caps Over $80M To Watch - Simply Wall St
State Street Corp Purchases 16,188 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation - The Bakersfield Californian
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge - GlobeNewswire
Aldeyra Therapeutics: Key Inflection Point Ahead (NASDAQ:ALDX) - Seeking Alpha
4 Stock-ing Stuffers for Under $10 a Share - TheStreet
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
BNP Paribas Financial Markets Acquires 10,201 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Sold by Verition Fund Management LLC - MarketBeat
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? - MSN
Aldeyra stock retains Outperform rating on strong DED drug outlook By Investing.com - Investing.com Australia
Aldeyra stock retains Outperform rating on strong DED drug outlook - Investing.com
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Down 12.3% in November - Defense World
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Drops By 12.3% - MarketBeat
Objective long/short (ALDX) Report - Stock Traders Daily
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short Interest - MarketBeat
Aldeyra Therapeutics CEO to Present at Citi Healthcare Conference Ophthalmology Panel - StockTitan
Final Deadline Alert: ALDX Investor Alert: Contact Bronstein, Ge - GuruFocus.com
Eagle Asset Management Inc. Lowers Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
Aldeyra announces FDA acceptance of resubmitted reproxalap application - MSN
Top US Penny Stocks To Watch In November 2024 - Simply Wall St
Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 - Reuters.com
Aldeyra Therapeutics (ALDX) Refiles NDA for Innovative Dry Eye Drug Reproxalap - GuruFocus.com
5,578 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Bought by US Bancorp DE - Defense World
BTIG sets shares target with buy rating on Aldeyra, cites FDA read - Investing.com
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application - MarketWatch
FDA reviews Aldeyra's dry eye disease drug candidate By Investing.com - Investing.com Canada
Aldeyra announces FDA acceptance of resubmitted reproxalap application (NASDAQ:ALDX) - Seeking Alpha
FDA reviews Aldeyra's dry eye disease drug candidate - Investing.com
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
What is Leerink Partnrs' Forecast for ALDX FY2024 Earnings? - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update - MarketBeat
Research Analysts Issue Forecasts for ALDX FY2028 Earnings - MarketBeat
Aldeyra Therapeutics CEO to Present at Jefferies London Healthcare Conference | ALDX Stock News - StockTitan
Aldeyra Therapeutics Insiders Who Sold Avert US$58m Market Cap Dip - Simply Wall St
Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) - Seeking Alpha
Nephrotic Syndrome Drugs Market Analysis of the Competitive - openPR
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
(ALDX) Trading Advice - Stock Traders Daily
Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):